A6X Stock Chart & Stats
€0.21
<€0.01(1.32%)
At close: 4:00 PM EST
€0.21
<€0.01(1.32%)
Day’s Range― - ―
52-Week Range€0.07 - €0.32
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€17.64M
Enterprise Value€95.80
Total Cash (Recent Filing)€4.00M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-0.04
Next Earnings
Aug 27, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding67,729,120
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.30
Price to Book (P/B)2.33
Price to Sales (P/S)6.68
P/FCF Ratio-7.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.03
Revenue Forecast (FY)€2.91M
Bulls Say, Bears Say
Bulls Say
Proprietary Active IngredientaXichem’s focus on a proprietary active ingredient, phenylcapsaicin, creates a durable asset base. A single, novel compound tailored to feed and related industrial uses supports differentiated product positioning, potential licensing, and higher barriers to entry versus commodity additives.
Low Financial LeverageA debt-free balance sheet with substantial equity reduces refinancing and interest-rate risk, giving the company optionality to fund R&D or scale through equity or strategic partnerships. This structural strength preserves strategic flexibility over the medium term.
Margin Recovery And Revenue ScaleImproved gross margin and rising trailing revenue indicate the business is beginning to leverage scale or improve cost structure. Sustained margin recovery alongside modest revenue expansion is a positive signal for moving toward durable profitability if trends continue.
Bears Say
Persistent Cash BurnNegative operating and free cash flow show the business consumes cash to operate and grow. Over months this necessitates external financing or equity dilution, constraining investment choices, increasing funding risk, and pressuring long-term viability absent sustained cash-flow improvement.
Deep Operating LossesVery large negative operating and net margins reflect that core operations are not profitable and are eroding returns on equity. Persistent losses can deplete equity, limit reinvestment, and require strategic shifts or financing to reach sustainable profitability over the medium term.
Small Scale And Commercialization UncertaintyRevenue relies on a single proprietary ingredient and commercial pathway (feed additives), with no disclosed major partners or recurring licensing streams. Low employee count and limited visible commercialization traction increase execution risk in scaling sales and distribution channels.
aXichem AB Class A News
A6X FAQ
What was aXichem AB Class A’s price range in the past 12 months?
aXichem AB Class A lowest stock price was €0.07 and its highest was €0.32 in the past 12 months.
What is aXichem AB Class A’s market cap?
aXichem AB Class A’s market cap is €17.64M.
When is aXichem AB Class A’s upcoming earnings report date?
aXichem AB Class A’s upcoming earnings report date is Aug 27, 2026 which is in 11 days.
How were aXichem AB Class A’s earnings last quarter?
aXichem AB Class A released its earnings results on May 21, 2026. The company reported -€0.012 earnings per share for the quarter, the consensus estimate of -€0.012 by €0.
Is aXichem AB Class A overvalued?
According to Wall Street analysts aXichem AB Class A’s price is currently Overvalued.
Does aXichem AB Class A pay dividends?
aXichem AB Class A does not currently pay dividends.
What is aXichem AB Class A’s EPS estimate?
aXichem AB Class A’s EPS estimate is -0.01.
How many shares outstanding does aXichem AB Class A have?
aXichem AB Class A has 67,729,120 shares outstanding.
What happened to aXichem AB Class A’s price movement after its last earnings report?
aXichem AB Class A reported an EPS of -€0.012 in its last earnings report, expectations of -€0.012. Following the earnings report the stock price went up 4.301%.
Which hedge fund is a major shareholder of aXichem AB Class A?
Currently, no hedge funds are holding shares in DE:A6X
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
aXichem AB Class A
aXichem AB is a biotechnology firm, established in 2007 and headquartered in Malmö, Sweden, that specializes in creating natural analogue compounds. The company offers aXivite, a capsaicin analogue solution designed for various dietary health applications. Another key product, aXiphen-bio, functions as a biological repellent, providing antifouling protection for marine vessels and installations, and managing pests in agriculture, forestry, and for safeguarding cable infrastructure both within buildings and underground. Additionally, aXiphen-feed is developed to boost the health of poultry, including chickens and hens, as well as swine, such as pigs and piglets.
Technical Analysis
Nexam Chemical Holding AB
―
―
Svenska Aerogel Holding AB
―
OrganoClick AB
―
XP Chemistries AB
―